Experts from Hong Kong are recommending cardiac evaluation of surviving relatives and next-generation sequencing (NGS) molecular autopsy as components of forensic investigations for young victims of sudden cardiac death (SCD).
An additional benefit of canagliflozin when administered to patients with type 2 diabetes (T2D) and high cardiovascular (CV) risk may be a reduced risk of stroke, according to results from the CANVAS* Program.
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
More home blood pressure (BP) and office BP measurements should be encouraged to identify otherwise hidden cases of hypertension, said an expert.
Despite increased availability of treatment options, hypertension and associated comorbidities remain a substantial public health concern, says an expert.
Individuals previously diagnosed with dilated cardiomyopathy (DCM) who are considered recovered from their condition may still need to continue treatment, with a higher rate of relapse observed among patients who discontinued versus continued therapy, according to the TRED-HF* trial findings presented at AHA 2018.